PRECISE: Preoperative Radiotherapy to Elicit Critical Immune Stimulating Effects
Overview
- Phase
- Phase 2
- Intervention
- Radiation Therapy
- Conditions
- Estrogen Receptor Positive
- Sponsor
- M.D. Anderson Cancer Center
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- Evaluation of Change in Percent of Tumor-Infiltrating Lymphocytes (TIL)
- Status
- Active, not recruiting
- Last Updated
- last month
Overview
Brief Summary
This phase II trial studies how well radiation therapy before surgery works in treating patients with hormone receptor positive, HER2 negative breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Detailed Description
PRIMARY OBJECTIVES: I. To evaluate the change in percent tumor-infiltrating lymphocytes (TIL) as a continuous variable before and after preoperative boost radiotherapy (RT) in hormone receptor (HR)+/human epidermal growth factor receptor2 (HER2)- breast cancers. SECONDARY OBJECTIVES: I. To evaluate the safety of preoperative boost RT administered to patients with HR+/HER2- breast cancer. EXPLORATORY OBJECTIVES: * I. To assess the mechanisms of cell death induced by preoperative boost RT. * II. To assess immunologic and molecular responses to preoperative boost RT. * III. To assess the correlations between immune markers, cell death markers, and their changes during treatment. * IV. To determine if magnetic resonance imaging (MRI) can be used to predict breast tumor response to neoadjuvant radiation. OUTLINE: Patients undergo boost radiation therapy 6-8 days before breast surgery. After surgery, patients continue to receive standard of care radiation therapy. After completion of study treatment, patients are followed up at 6 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \>/=18 years at time of study entry
- •Histologically confirmed HR+/HER2- (according to American Society of Clinical Oncology/College of American Pathologists guidelines) invasive carcinoma of the breast
- •Presence of a clip in the primary breast cancer
- •Biopsy-amenable residual disease in the breast measuring \>/= 1cm in at least one dimension on ultrasound cm in at least one dimension on ultrasound
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •Signed written informed consent
- •Planned for multidisciplinary evaluation by a Breast Surgical Oncologist and Breast Radiation Oncologist. For patients undergoing mastectomy and desirous of reconstruction or those undergoing breast conservation in whom oncoplastic local tissue rearrangement or reduction mammoplasty is being considered, this multidisciplinary evaluation will also include a plastic surgeon.
Exclusion Criteria
- •Women who are pregnant or breast-feeding
- •Contraindication to receive radiotherapy
Arms & Interventions
Treatment (radiation therapy, surgery)
Patients undergo boost radiation therapy 6-8 days before breast surgery. After surgery, patients continue to receive standard of care radiation therapy.
Intervention: Radiation Therapy
Treatment (radiation therapy, surgery)
Patients undergo boost radiation therapy 6-8 days before breast surgery. After surgery, patients continue to receive standard of care radiation therapy.
Intervention: Therapeutic Conventional Surgery
Outcomes
Primary Outcomes
Evaluation of Change in Percent of Tumor-Infiltrating Lymphocytes (TIL)
Time Frame: 6 to 8 days after preoperative radiotherapy
With 20 patients, a 95% confidence interval for the mean difference between TIL measurements would extend 0.44\*s units from the mean (where "s" is the standard deviation of the TIL differences). If the differences are not normally distributed, researchers will report the median difference along with appropriate 95% confidence intervals. Appropriate graphs used to visualize the data.
Secondary Outcomes
- Delay Rate of Surgery Following Boost RT(4 weeks after boost RT)
- Tumor Changes between pre and post boost(Up to 4 weeks after surgery)
- Changes in dynamic contrast enhanced (DCE)(4 weeks after surgery)
- Toxicity calculated using the CTCAE v4.0(6 months after adjuvant RT)